ScholarLens Back to search
2013•Medical Journal of Chinese People's HealthRequires access

A comparative study of Escitalopram combined with Aripiprazole in the treatment of refractory depression

Liao Qiu

Open publisher page 0 citations

Abstract

Objective:To explore the efficacy and safety of Escitalopram combined with Aripiprazole in the treatment of refractory depression.Methods:A total of 64 patients with refractory depression were randomly divided into the study group with Escitalopram combined with Aripiprazole and the control group with Escitalopram for 8 weeks of treatment.The clinical efficacy and side effects were assessed with Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA) and Treatment Emergent symptom Scale(TESS).Results: After treatment,the scores of HAMD and HAMA in two groups were both significantly lower than those before treatment.On the 2nd、4th、6th and 8th weekend of treatment,the scores of HAMD and HAMA in study group were significantly lower than those in control group.No severe side effects were found in two groups.Conclusions: Escitalopram combined with Aripiprazole has better effect than escitalopram single in the treatment of refractory depression with satisfactory tolerability.

About this research paper

What this paper is about

Objective:To explore the efficacy and safety of Escitalopram combined with Aripiprazole in the treatment of refractory depression.Methods:A total of 64 patients with refractory depression were randomly divided into the study group with Escitalopram combined with Aripiprazole and the control group with Escitalopram for 8 weeks of treatment.The clinical efficacy and side effects were assessed with Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA) and Treatment Emergent symptom Scale(TESS).Results: After treatment,the scores of HAMD and HAMA in two groups were both significantly lower than those before treatment.On the 2nd、4th、6th and 8th weekend of treatment,the scores of HAMD and HAMA in study group were significantly lower than those in control group.No severe side effects were found in two groups.Conclusions: Escitalopram combined with Aripiprazole has better effect than escitalopram single in the treatment of refractory depression with satisfactory tolerability.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To explore the efficacy and safety of Escitalopram combined with Aripiprazole in the treatment of refractory depression.Methods:A total of 64 patients with refractory depression were randomly divided into the study group with Escitalopram combined with Aripiprazole and the control group with Escitalopram for 8 weeks of treatment.The clinical efficacy and side effects were assessed with Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA) and Treatment Emergent symptom Scale(TESS).Results: After treatment,the scores of HAMD and HAMA in two groups were both significantly lower than those before treatment.On the 2nd、4th、6th and 8th weekend of treatment,the scores of HAMD and HAMA in study group were significantly lower than those in control group.No severe side effects were found in two groups.Conclusions: Escitalopram combined with Aripiprazole has better effect than escitalopram single in the treatment of refractory depression with satisfactory tolerability.

Key concepts: Escitalopram, Aripiprazole, Hamd, Tolerability, Depression (economics), Refractory (planetary science), Psychology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A comparative study of Escitalopram combined with Aripiprazole in the treatment of refractory depression — Research Paper | ScholarLens